The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.
Age >/= 18 years, or considered an adult by local regulations, at the time of consent
Signed informed consent
Histologically or cytologically confirmed SCLC. Received 1L platinum-based systemic therapy and had documented disease progression during or after the most recent systemic therapy. Or received 2L tarlatamab is allowed.
Measurable disease according to RECIST v1.1 as assessed by the investigator.
Received more than one line of systemic therapy for Extensive-Stage SCLC.
Received any prior ADC with topoisomerase 1 inhibitor payload
Participants with another known malignancy with exceptions defined in the protocol.
History or suspected ILD/pneumonitis based on criteria per protocol
Zai Lab (Shanghai) Co., Ltd.
Lead sponsor
Zai Lab (US) LLC
Collaborator